Alzheimer's Research Advances Focus on Diagnosis and Risk Prediction
New insights into Alzheimer's blood tests for improving diagnosis and predicting future cognitive decline were presented at the 2026 Alzheimer's Association International Conference.
The 2026 Alzheimer's Association International Conference (AAIC) showcased significant research advancements in the diagnosis and prediction of Alzheimer's disease.
A large-scale study in Sweden demonstrated that Alzheimer's blood test results enabled primary care physicians to diagnose the disease with nearly the same accuracy as specialists. Concurrently, extensive research suggests that measuring the protein p-tau217 in blood could help predict cognitive decline up to five to ten years before symptoms manifest.
Further findings presented included the global adaptation of a successful lifestyle intervention that improved cognitive abilities in older adults at risk in Latin America. Additionally, a promising treatment for agitation in advanced Alzheimer's was discussed, alongside new data on the brain health risks associated with playing soccer.
The AAIC serves as the premier annual gathering for disseminating the latest Alzheimer's and dementia research, attracting over 11,000 attendees and featuring more than 7,800 scientific submissions for this year's event in London and online.